Printer Friendly

CYTOGEN ANNOUNCES SATISFACTION WITH PRODUCT LAUNCH

 PRINCETON, N.J., March 16 /PRNewswire/ -- At an investment conference sponsored by Cowen & Company today in Boston, Cytogen Corporation (NASDAQ: CYTO) indicated its satisfaction with the launch status of OncoScint CR/OV, the first FDA-approved monoclonal antibody- based imaging agent for colorectal and ovarian cancer, and updated analysts on the progress of OncoScint Prostate, currently in Phase III trials.
 Cytogen Group Vice President and Chief Financial Officer Martin D. Cleary announced that of the 65 education workshops scheduled for nuclear medicine professionals across the country, 32 have been successfully completed. "We have receivev?ery positive feedback from the nuclear medicine technologists who have attended the OncoScint CR/OV workshop, with the majority indicating that OncoScint CR/OV provides significant incremental information for the management and treatment of colorectal and ovarian cancers," said Cleary. "We are very pleased with this result, and look forward to promoting the product to oncologists and surgeons who will actually order the OncoScint procedure for their patients after the workshops are completed in late April."
 Cytogen President Dr. Thomas J. McKearn further indicated that enrollment in the Phase III studies for OncoScint Prostate is proceeding on schedule. The company expects to file a Product License Application for the diagnosis of lymph node metastases later in 1993. "In Phase II studies with OncoScint Prostate, lymph node metastases that were missed by CT and/or MRI images were successfully detected, and subsequently surgically confirmed, in 52 percent of patients imaged with OncoScint PR. This finding is remarkable since there are currently no non- invasive diagnostic modalities that can definitively diagnose lymph node metastases in prostate cancer patients."
 Cytogen is a biopharmaceutical company engaged in the development of products utilizing monoclonal antibodies for the targeted delivery of diagnostic and therapeutic substances directly to sites of disease. Cytogen uses its patented proprietary antibody "linker" technology primarily to develop specific cancer diagnostic imaging and cancer therapeutic products.
 /delval/
 -0- 3/16/93
 /CONTACT: Mary Beals, director of Corporate Communications of Cytogen, 609-987-8221/
 (CYTO)


CO: Cytogen Corporation ST: New Jersey IN: MTC SU:

MK -- PH030 -- 6673 03/16/93 15:30 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 16, 1993
Words:350
Previous Article:LAWYERS UNVEIL HANDBOOK FOR PEOPLE WITH DISABILITIES
Next Article:TAPISTRON INTERNATIONAL REPORTS SUBSTANTIAL INCREASE IN SECOND QUARTER RESULTS
Topics:


Related Articles
CYTOGEN ANNOUNCES APPOINTMENT OF REGIONAL SALES MANAGERS
CYTOGEN AND CYTORAD ANNOUNCE AGREEMENT TO MERGE
CYTOGEN CORPORATION REPORTS ON DEVELOPMENTS CONNECTED WITH SEC FILING
CYTOGEN CORPORATION ISSUES ANNOUNCEMENT
CYTOGEN RAISES $7.3 MILLION
CYTOGEN Corporation Issues Letter to Stockholders
CYTOGEN Updates Stockholders at Annual Meeting; Highlights Include Quadramet Launch Today by DuPont Merck Radiopharmaceuticals and Corporate...
CYTOGEN Issues Letter to Stockholders
CYTOGEN Participates In Prostate Cancer Awareness Week
CYTOGEN Secures $12 Million Equity Line.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters